ERBB2 and gastroesophageal junction adenocarcinoma: Pembrolizumab has also been recently studied in locally advanced resectable gastric and gastroesophageal junction adenocarcinoma as well as early‐stage estrogen receptor‐positive/human epidermal growth factor receptor 2‐negative breast cancer as a neoadjuvant‐adjuvant regimen.